All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Induction with lower-intensity CPX-351 + venetoclax in patients with AML: Results from a phase 1b trial
|
Results from a phase Ib, multicenter, open-label study (NCT04038437), evaluating the combination of lower-intensity CPX-351 and venetoclax in adults with AML who are unfit/ineligible for IC, were published in Blood Advances by Uy et al.1 A total of 35 patients were enrolled and received CPX-351 at 20 units/m2 (DL1; n = 4), 40 units/m2 (DL2; n = 7), or 30 units/m2 (DL1b; n = 24) during the dose-exploration phase. |
| Key learnings |
| No DLTs occurred in patients receiving DL1, while one of six patients at DL2 experienced two DLTs. Three patients receiving DL1b showed no DLTs and had a safety profile comparable with that of DL1. The RP2D was CPX-351 at 30 units/m2 [daunorubicin 13.2 mg/m2 and cytarabine 30 mg/m2] plus venetoclax 400 mg. |
| Most frequently reported TEAEs were nausea (42.9%), thrombocytopenia (40.0%), febrile neutropenia (37.1%), and neutropenia (34.3%). A total of 20% of patients had TEAEs leading to treatment discontinuation. By Day 60, the early mortality rate was 11.4%, with one death at DL1 (non-treatment-related myocardial infarction) and three at DL1b (treated-related worsening of lung function, n = 1; disease progression, n = 2). |
| ORR was 51.4%. CR/CRi was achieved by 54.8% of the evaluable patients (n = 31), of which 14 were MRD negative. CR/CRi rate was 57.7% in patients with wild-type TP53 (n = 26) and 12.5% in patients with TP53m AML (n = 8). |
| The findings indicate that lower-intensity CPX-351 + venetoclax is a well-tolerated alternative to HMA + venetoclax as induction therapy for adult and older patients with AML who do not have TP53 mutations and are unfit/ineligible for IC. |
Abbreviations: AE, adverse event; AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; DL, dose-level; DLT, dose-limiting toxicity; HMA, hypomethylating agent; IC, intensive chemotherapy; MRD, measurable residual disease; ORR, overall response rate; RP2D, recommended phase II dose; TEAE, treatment-emergent AE.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
